Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Jean-Nicolas Vaillant"'
Autor:
Emilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, Audrey Perret, Claire Gallois, Maria Antista, Lorenzo Pilla, Thierry Lecomte, Mario Scartozzi, Emilie Soularue, Lisa Salvatore, Vincent Bourgeois, Massimiliano Salati, David Tougeron, Ludovic Evesque, Jean-Nicolas Vaillant, Reem El-Khoury, Sara Lonardi, Chiara Cremolini, Julien Taieb
Publikováno v:
European journal of cancer (Oxford, England : 1990). 168
Encorafenib plus cetuximab is efficient in anti-EGFR-naïve patients with BRAFWe retrospectively collected a series of patients with BRAFm mCRC treated with B + E after previous anti-EGFR treatment, in 14 centers. Progression-free survival (PFS) and
Autor:
Astrid Lièvre, Christophe Penna, Laurent Teillet, Robert Malafosse, Stéphane Benoist, Bernard Nordlinger, Tristan Cudennec, Philippe Rougier, Frédérique Peschaud, Valérie Laurent, Jean-Nicolas Vaillant, Céline Lepère, Catherine Julié, Emmanuel Mitry
Publikováno v:
Digestive and Liver Disease. 46:838-845
Background Few data are available on management of very elderly colon cancer patients, especially concerning the parameters of therapeutic decisions and the role of geriatricians. Methods We retrospectively reviewed the charts of patients over 80 yea
Autor:
Julien Taieb, Jean-Nicolas Vaillant, Emmanuelle Samalin, Emmanuel Mitry, Laetitia Dahan, Hajer Turki, Jean-François Seitz, Philippe Rougier, Céline Lepère, Bruno Landi, Aziz Zaanan, Cécile Dalban, Simon Pernot, Marc Ychou, Thibault Mazard
Publikováno v:
Gastric Cancer. 17:341-347
Docetaxel-cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, which it can effectively replace in this s
Autor:
Isabelle Trouilloud, Theofano Markoutsaki, C. Lepere, Bertrand Brieau, Anne Berger, Jean-Nicolas Vaillant, Bruno Landi, Philippe Rougier, Hélène Roussel, Olivier Dubreuil, Julien Taieb, Aziz Zaanan
Publikováno v:
Clinics and Research in Hepatology and Gastroenterology. 37:289-295
The development of ovarian metastases from gastric cancer indicates a turning point of the disease progression and is usually associated with poor prognosis. Efficacy of modern chemotherapy protocols in ovarian metastases from gastric cancer is unkno
Autor:
Christophe Penna, Philippe Rougier, Emmanuel Mitry, Gilles Declety, Céline Lepère, Martin Housset, Henri Parlier, Yves Otmezguine, Jean-Baptiste Bachet, C. Julié, Jean-Nicolas Vaillant, B. Nordlinger
Publikováno v:
Gastroentérologie Clinique et Biologique. 31:151-156
Resume Objectifs La radio-chimiotherapie est le traitement standard des adenocarcinomes localement evolues non resecables du pancreas (ALEP). La chimiotherapie a prouve son efficacite en situation metastatique et nous avons voulu evaluer son utilisat
Publikováno v:
Bulletin de l'Académie Nationale de Médecine. 187:881-892
The 5-year risk of progression after complete resection of liver metastases is of 50% to 75%. Trials which have evaluated adjuvant systemic chemotherapy using 5FU--folinic acid, sometimes in association with intra-arterial chemotherapy, are not power
Autor:
Frédérique Maindrault-Goebel, Philippe Rougier, Yves Otmezguine, Suzy Rakotomalala, Jean-Nicolas Vaillant, Céline Lepère, Emmanuel Mitry, Catherine Julié
Publikováno v:
Gastroentérologie Clinique et Biologique. 31:445-447
Resume Les carcinomes endocrines peu differencies sont des tumeurs rares, caracterisees par une grande agressivite et un pronostic mediocre. La plupart des malades ont une maladie metastatique au moment du diagnostic et ne peuvent donc beneficier d
Autor:
Hélène Radvani, Jean-Nicolas Vaillant, Pierre Laurent-Puig, Marie-Christine Clavero-Fabri, Philippe Rougier, Bernard Nordlinger, Catherine Julié, Nicolas Goasguen
Publikováno v:
Gastroentérologie Clinique et Biologique. 28:1165-1167
Resume La decouverte d’une deuxieme localisation adenocarcinomateuse chez un malade pose le probleme de l’origine de cette nouvelle lesion (primitive ou metastatique). Si parfois l’evolution clinique ou la localisation de cette nouvelle lesion
Autor:
Jean-Nicolas Vaillant, Philippe Rougier, Céline Lepère, Meriem Serghini, Tarek Boussaha, Julien Taieb, Olivier Dubreuil, Bruno Landi
Publikováno v:
Cancéro digest.
Autor:
Marc Ychou, Jean-Nicolas Vaillant, Christine Boyer-Gestin, Jean-Baptiste Bachet, Céline Lepère, Philippe Rougier, Eric Assenat, Astrid Lièvre, Emmanuel Mitry, Emmanuelle Samalin, Fabienne Portales
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 347 (2009)
BMC Cancer, Vol 9, Iss 1, p 347 (2009)
Background The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it wa